866-997-4948(US-Canada Toll Free)

Global Idiopathic Pulmonary Fibrosis 2016-2020

Published By :

Technavio

Published Date : May 2016

Category :

Metabolic Disorders

No. of Pages : 60 Pages

About Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment.

Technavios analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Idiopathic Pulmonary Fibrosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Baxter International
Boehringer Ingelheim
F.Hoffmann-La Roche
Prometheus Laboratories

Other prominent vendors
Afferent Pharmaceuticals
Amgen
Biogen
Bristol-Myers Squibb
Cipla
FibroGen
Gilead Sciences
GlaxoSmithKline
GNI Group
Horizon Pharma
ImmuneWorks
MediciNova
MedImmune (subsidiary of AstraZeneca)
Novartis
Pfizer
Promedior
ProMetic Life Sciences
Sanofi
Shionogi
Zai Lab

Market driver
Unmet medical need
For a full, detailed list, view our report

Market challenge
Lack of proper diagnosis
For a full, detailed list, view our report

Market trend
Patient assistance programs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Pathogenesis
Signs and symptoms
Diagnosis
Management
Epidemiology
PART 06: Pipeline analysis
Lebrikizumab
Tipelukast
Tralokinumab
FG-3019
Simtuzumab
BMS-986020
AF-219
SAR156597
BG00011
PRM-151
PBI-4050
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by ROA
Oral
Parenteral
PART 09: Market segmentation by drug class
Systemic corticosteroids
Immunosuppressants
Tyrosine kinase inhibitors
Anti-fibrotic agents
PART 10: Geographical segmentation
Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020
Idiopathic pulmonary fibrosis market in Americas
Idiopathic pulmonary fibrosis market in EMEA
Idiopathic pulmonary fibrosis market in APAC
PART 11: Market drivers
Special regulatory designations for pipeline candidates
Growth in patient population
Unmet medical needs
PART 12: Impact of drivers
PART 13: Market challenges
Unknown disease etiology
Lack of proper diagnosis
Increased use of off-label and alternative therapies
PART 14: Impact of drivers and challenges
PART 15: Market trends
Patient assistance programs
Increase in M&A
Rise in public awareness
PART 16: Vendor landscape
Competitive scenario
Market share analysis 2015
Baxter International
Boehringer Ingelheim
F Hoffmann-La Roche
Prometheus Laboratories
Other prominent vendors
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis
Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis
Exhibit 04: Treatment options for idiopathic pulmonary fibrosis
Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis
Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio
Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA
Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class
Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015
Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions)
Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions)
Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions)
Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions)
Exhibit 16: Key drivers
Exhibit 17: Impact of drivers
Exhibit 18: Key challenges
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Key trends
Exhibit 21: Baxter International: Business segmentation by revenue 2014
Exhibit 22: Baxter International: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: Baxter International: Geographical segmentation by revenue 2014
Exhibit 24: Baxter International: Key takeaways
Exhibit 25: Boehringer Ingelheim: Business segmentation by revenue 2014
Exhibit 26: Boehringer Ingelheim: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 27: Boehringer Ingelheim: Geographical segmentation by revenue 2014
Exhibit 28: Boehringer Ingelheim: Key takeaways
Exhibit 29: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 30: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 31: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 32: F Hoffmann-La Roche: YoY growth and revenue generated from CellCept 2011-2014 ($ millions)
Exhibit 33: F.Hoffmann-La Roche: Key takeaways
Exhibit 34: Prometheus Laboratories: Product categories
Exhibit 35: Prometheus Laboratories: Key takeaways

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *